Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
China Set to Exit Deflation Cycle in Early 2026, ANZ Analysts Say 
Gold Prices Surge to Three-Week High as Trump-Iran Ceasefire Weakens Dollar 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Asian Markets Retreat as Gulf Crisis Fuels Oil Surge and Inflation Fears 
Oil Prices Crash 15% as Trump and Iran Agree to Two-Week Ceasefire 
Australia's Social Media Ban for Under-16s Sparks Global Movement 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Asian Currencies Rally as Dollar Weakens, Trump-Iran Ceasefire Boosts Risk Sentiment 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Asian Currencies Hold Steady as Middle East Ceasefire Doubts Weigh on Markets 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo 
Britain Courts Anthropic Amid US Defense Department Dispute 
Dollar Stabilizes Amid Fragile US-Iran Ceasefire as Markets Watch Hormuz Strait 
Japan Consumer Confidence Drops Sharply Amid Rising Fuel Costs and Middle East Tensions 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
